The National Medical Products Administration in China has accepted the biologics license application for zanidatamab for the second-line treatment of patients with HER2-positive biliary tract cancer. The Ministry of Health, Labour and Welfare of Japan has granted approval for a new blood cancer therapy by GSK. Takeda has announced the approval of LIVTENCITY® (maribavir) in Japan for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies. Daiichi Sankyo and Dizal have received approval in Asia for new treatments for relapsed or refractory peripheral T-cell lymphoma, a rare form of non-Hodgkin lymphoma. Fruquintinib has won European approval for pretreated metastatic colorectal cancer (mCRC). Additionally, Valemetostat Tosilate has been approved in Japan for relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). Momelotinib has also received Japanese approval for the treatment of myelofibrosis.
Momelotinib Wins Japanese Approval for Myelofibrosis #mpnsm #MedTwitter https://t.co/Oaj315ImnM
Valemetostat Tosilate Approved in Japan for R/R PTCL #leusm #oncology https://t.co/BA2o8NzjrB
Fruquintinib Wins European Approval for Pretreated mCRC #crcsm #oncology https://t.co/AH9gACgKON
Daiichi Sankyo and Dizal get approval in Asia for new treatments for relapsed or refractory peripheral T-cell lymphoma, a rare form of non-Hodgkin lymphoma. #oncology #PTCL https://t.co/dpVFilfojM
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies $TAK https://t.co/g0VbqY1Jw5
#News for #Investors and #Media: The Ministry of Health, Labour and Welfare of Japan has granted approval for our blood cancer therapy. Learn more: https://t.co/Uj2IpARFtZ https://t.co/87Z4yiIDLp
The National Medical Products Administration in China has accepted the biologics license application for zanidatamab for the second-line treatment of patients with HER2-positive biliary tract cancer. #oncology #medtwitter https://t.co/2HXkA6LFjd https://t.co/HDQClwZAVm